Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Clostridium difficile vaccine (Primary)
- Indications Clostridium infections
- Focus Registrational; Therapeutic Use
- Acronyms Cdiffense
- Sponsors sanofi pasteur
- 11 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2019.
- 11 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2019.
- 11 May 2017 Status changed from active, no longer recruiting to recruiting.